Sodium Thiosulfate

CAS RN: 7772-98-7

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) ANIMAL STUDIES
      • 1) Rapid intravenous infusion of large amounts has caused transient hypotension and ECG changes in dogs.
      • 2) Metabolic acidosis and hypernatremia occurred in dogs given large doses.
    • B) WITH POISONING/EXPOSURE
      • 1) Sodium thiosulfate is an agent with a low order of toxicity. It may be a mild irritant in the solid form. Ingestion can cause gastrointestinal disturbances. It can cause allergic dermatitis.
      • 2) Ingestion of a large quantity may cause diarrhea.
0.2.3 VITAL SIGNS0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) WITH POISONING/EXPOSURE
      • 1) Ingestion of large doses may result in gastroenteritis and a cathartic action.
0.2.20 REPRODUCTIVE HAZARDS
  • A) Sodium thiosulfate is classified as FDA pregnancy category C. There are no adequate and well-controlled studies of sodium thiosulfate use in pregnant women. Animal studies indicated no teratogenic effects occurred when hamsters were given IV sodium thiosulfate in doses similar to those used for cyanide poisoning in humans, and no embryotoxicity or teratogenicity was reported for mice, rats, or rabbits . It is unknown whether systemic sodium thiosulfate is excreted in breast milk, although the WHO states that the topical form is compatible with breastfeeding. Studies to evaluate the potential effects of sodium thiosulfate use on human fertility are not available.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS7772-98-7 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
Find more information on this substance at: PubChem, PubMed